Pomalyst (Pomalidomide) Patent Expiration, LOE Window & CMS Spending

Pomalyst (Pomalidomide) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2031-12-21, 10 AB generics, $2.25B 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN204026 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-12-21
Last Listed Patent or Exclusivity Date2031-12-21
Orange Book Patents (*PED Extensions)6 patents (3 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$2.25B
2024 Medicare Part D Spend$2.15B
2024 Medicaid Spend$103.7M
Reported Wholesale Price Change (CA SB 17)24 WAC filings (max 20.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.